In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...

FDA reviewers flag "discordant results" in a briefing document published ahead of Friday's advisory committee meeting for the ...

In the first 6 months of 2025, 385 employees resigned from the Center for Drug Evaluation and Research, compared with under ...

BioSpace poll, and over half are considering it. Two recruitment experts, a fractional worker and an aspiring fractional ...

Participants in trials of BrainStorm Cell Therapeutics' NurOwn filed a Citizens’ Petition with the FDA earlier this month ...

Johnson & Johnson's $23.7 billion in second-quarter earnings, driven by cancer and neuroscience drugs, exceeded analyst ...

Following the death of two teenage patients with Duchenne muscular dystrophy following Elevidys treatment, Sarepta ...

Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

With venture funding tightening in the post-COVID landscape, efficiency has become more critical than ever. In this ...

Looking for a biopharma job in Illinois? Check out the BioSpace list of six companies hiring life sciences professionals like you.

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival and reduce hospitalizations, but the company sees promise in data from an ...